window.dataLayer = window.dataLayer || []; function gtag(){dataLayer.push(arguments);} gtag('js', new Date()); gtag('config', 'UA-113618785-2');


About admin

This author has not yet filled in any details.
So far admin has created 49 blog entries.

HalioDx Immunoscore® identifies candidates for Phase II Colorectal Cancer Trial

2020-09-17T09:47:14+00:00September 16th, 2020|

We report more exciting news about the Immunoscore® diagnostic tool developed by our partners at HalioDx! The immuno-oncology diagnostic company, HalioDx announced last week that it has entered into a Collaboration Agreement with the FFCD, the French Cooperative Group dedicated exclusively to digestive oncology, on the Phase II multi-center POCHI trial (FFCD1703 - NCT04262687) in which [...]

HalioDx Immunoscore® embedded in 2020 ESMO Clinical Practice Guidelines

2020-09-02T10:44:29+00:00September 1st, 2020|

Our partners at HalioDx SAS, an immuno-oncology diagnostic company headquartered in Marseille, France, recently announced that their diagnostic test Immunoscore® has been included in the 2020 European Society of Medical Oncology (ESMO) Clinical Practice Guidelines for Diagnosis, Treatment and Follow-up for Localised Colon Cancer. Immunoscore® was considered for its ability to refine the prognosis for [...]

COLOSSUS publication in Science Translational Medicine, August 2020

2020-08-18T12:24:03+00:00August 18th, 2020|

Congratulations to the team of Barbara Lupo, Francesco Sassi, Marika Pinnelli, Francesco Galimi, Eugenia R. Zanella, Valentina Vurchio, Giorgia Migliardi, Paolo Armando Gagliardi, Alberto Puliafito, Daria Manganaro, Paolo Luraghi, Michael Kragh, Mikkel W. Pedersen, Ivan D. Horak, Carla Boccaccio, Enzo Medico, Luca Primo, Daniel Nichol, Inmaculada Spiteri, Timon Heide, Alexandra Vatsiou, Trevor A. Graham, Elena Élez, Guillem Argiles, Paolo Nuciforo, Andrea Sottoriva, Rodrigo Dienstmann, Diego Pasini, Elena Grassi, Claudio Isella, Andrea Bertotti and Livio Trusolino for their recent publication in Science Translational Medicine. The paper [...]

Partner News: Ireland establishes first National Preclinical Imaging Centre

2020-06-17T11:40:25+00:00June 17th, 2020|

Prof Annette Byrne, RCSI, COLOSSUS Coordinator, NPIC Director In Ireland, a new National Preclinical Imaging Centre (NPIC) which will provide enhanced research data to inform new clinical trials that aim to improve patient outcomes, has been awarded funding of €3.4 million under Science Foundation Ireland's (SFI) Research Infrastructure Programme. COLOSSUS Coordinator, Prof Annette [...]

Partner in the Spotlight: Halio Dx

2020-05-12T10:12:31+00:00May 12th, 2020|

This month we feature our partners at HalioDx. HalioDx ( is the pioneer of immuno-oncology diagnostic, a transforming approach of cancer care that benefits from novel and deep understanding of the tumour immune microenvironment. The company provides a unique and extensive range of proprietary assays that allow it to extract from the immune contexture of [...]

HalioDx Immunoscore® is independently reviewed in Molecular Diagnosis and Therapy

2020-04-17T09:07:23+00:00April 16th, 2020|

An independent review entitled “Immunoscore®: A Diagnostic Assay for Clinical Management of Colon Cancer” is published on March 30th, 2020 in Molecular Diagnosis and Therapy (Blair, H.A. Mol Diagn Ther (2020)[1] a specialized journal of Springer Nature group that provides researchers and healthcare professionals with insights into the latest molecular diagnostic and therapeutic techniques and their use [...]

COLOSSUS Partner in the Spotlight: Cancer Trials Ireland

2020-04-09T13:02:32+00:00April 9th, 2020|

Cancer Trials Ireland was established in 1996 under the name of Irish Cooperative Oncology Research Group (ICORG). A group of cancer consultants had the aim to create more opportunities for patients to access cutting edge treatments by putting a formal structure in place, which could make Ireland more attractive as a location to international cancer [...]

The COLOSSUS Spring 2020 newsletter is out!

2020-03-02T17:43:21+00:00March 2nd, 2020|

Hear ye! Hear ye! The Spring 2020 COLOSSUS newsletter is out now! Read the latest update on the COLOSSUS translational study from partners at Cancer Trials Ireland, a spotlight feature on our partner HalioDx, the dissemination round-up and much more!

VIB hosts Tumor Heterogeneity, Plasticity and Therapy meeting, 14-15 May 2020- travel grants are available

2020-02-25T16:45:08+00:00February 25th, 2020|

Our partners VIB,  a non-profit life sciences research institute in Belgium, is pleased to announce the first  Tumor Heterogeneity, Plasticity and Therapy meeting which will be held on May 14-15, 2020 in the historical city of Leuven, Belgium. The upcoming deadlines are: Travel Grant application deadline: 27 February 2020 Abstract deadline: 12 March 2020 When you submit your abstract for [...]

Go to Top